Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

I Am Rare, Deadly, and Can Make You Go Blind. What Am I?

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2025
Same author

Cancer-associated retinopathy secondary to gallbladder carcinoma.

GMS ophthalmology cases·2024
Same author

Recurrent multiple eye muscle palsy as a first sign of sarcoidosis.

GMS ophthalmology cases·2023
Same author

PROGRESSIVE RETINOPATHY IN A PATIENT WITH MUCOPOLYSACCHARIDOSIS TYPE II UNDERGOING ENZYME REPLACEMENT THERAPY: A CASE REPORT.

Retinal cases & brief reports·2023
Same author

CEP162 deficiency causes human retinal degeneration and reveals a dual role in ciliogenesis and neurogenesis.

The Journal of clinical investigation·2023
Same author

Optic Nerve Biopsies in Unexplained Progressive Optic Neuropathy in Two Adults Reveal Optic Nerve Gliomas.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2022

Related Experiment Video

Updated: Jan 6, 2026

Using the Electroretinogram to Assess Function in the Rodent Retina and the Protective Effects of Remote Limb Ischemic Preconditioning
06:34

Using the Electroretinogram to Assess Function in the Rodent Retina and the Protective Effects of Remote Limb Ischemic Preconditioning

Published on: June 9, 2015

16.8K

MITOGEN-ACTIVATED PROTEIN INHIBITORS: FULL-FIELD ELECTRORETINOGRAM DEMONSTRATING GENERALIZED RETINAL DYSFUNCTION.

Michel van Lint1, Herlinde Ebraert2, Elisabeth H Van Aken3

  • 1Department of Ophthalmology, Brussels University Hospital, Jette, Belgium. Dr. van Lint is now with the Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium.

Retinal Cases & Brief Reports
|October 5, 2019
PubMed
Summary

Mitogen-activated protein inhibitors like trametinib can cause widespread retinal toxicity. Reducing the dosage may improve vision and resolve retinal detachments, aiding in understanding these effects.

More Related Videos

Direct-Coupled Electroretinogram DC-ERG for Recording the Light-Evoked Electrical Responses of the Mouse Retinal Pigment Epithelium
09:10

Direct-Coupled Electroretinogram DC-ERG for Recording the Light-Evoked Electrical Responses of the Mouse Retinal Pigment Epithelium

Published on: July 14, 2020

5.7K
Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

18.8K

Related Experiment Videos

Last Updated: Jan 6, 2026

Using the Electroretinogram to Assess Function in the Rodent Retina and the Protective Effects of Remote Limb Ischemic Preconditioning
06:34

Using the Electroretinogram to Assess Function in the Rodent Retina and the Protective Effects of Remote Limb Ischemic Preconditioning

Published on: June 9, 2015

16.8K
Direct-Coupled Electroretinogram DC-ERG for Recording the Light-Evoked Electrical Responses of the Mouse Retinal Pigment Epithelium
09:10

Direct-Coupled Electroretinogram DC-ERG for Recording the Light-Evoked Electrical Responses of the Mouse Retinal Pigment Epithelium

Published on: July 14, 2020

5.7K
Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

18.8K

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Oncology

Background:

  • Mitogen-activated protein (MAP) kinase inhibitors are used in cancer therapy.
  • Retinal toxicity is a known side effect of some targeted therapies.

Observation:

  • A patient treated with the MAP kinase inhibitor trametinib developed generalized retinal toxicity.
  • Full-field electroretinogram (ffERG) revealed widespread retinal dysfunction.

Findings:

  • Trametinib-induced retinal toxicity manifested as generalized dysfunction, not solely posterior pole involvement.
  • Decreasing the trametinib dosage led to improved ffERG responses and resolution of serous detachments.

Implications:

  • MAP kinase inhibitors may impact global retinal function.
  • Understanding these mechanisms is crucial for managing ocular side effects in patients receiving targeted therapies.
  • This case highlights the importance of ffERG in detecting and monitoring diffuse retinal toxicity.